Decreased expression of peroxiredoxinl inhibits proliferation, invasion, and metastasis of ovarian cancer cell

• Published in: OncoTargets and therapy 2018-01, Vol.11, p.7745
• Main Authors: Zheng, Ming-Jun, Wang, Jing, Wang, Hui-Min, Gao, Ling-Ling, Li, Xiao, Zhang, Wen-Chao, Gou, Rui, Guo, Qian, Nie, Xin, Liu, Juan-Juan, Lin, Bei
• Format: Article
• Language: English
• Subjects: Analysis; Cancer cells; Cancer research; Genes; Genomics; Immunohistochemistry; Ovarian cancer; Ovarian tumors; Prognosis; Regression analysis; Tumors
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S175009

Aim: The aim of this study was to explore the expression of peroxiredoxinl (PRDX1) in epithelial ovarian cancer, analyze the relationship between PRDX1 and clinicopathologic parameters of patients with ovarian cancer, including their prognosis, and describe changes and the mechanisms involved in malignant biologic behavior of ovarian cancer cells when PRDX1 expression is inhibited. Methods: The expression of PRDX1 was detected immunohistochemically in 15 samples of normal ovarian tissue, 21 benign, 11 borderline, and 101 malignant epithelial ovarian tumors. Changes in ovarian cancer cell proliferation, invasion, and metastasis before and after inhibiting PRDX1 expression were assessed by cell function assay. Additionally, gene set enrichment analysis (GSEA) of PRDX1 was performed by the Cancer Genome Atlas database. A proteinprotein interaction network was then constructed and a pathway function analysis of the genes in the network was conducted. Results: PRDX1 expression was mainly localized to the cytoplasm, as well as the nucleus of cells. The expression rate of PRDX1 in epithelial ovarian malignant tissues (96.04%) was significantly higher than that in borderline (72.72%) and benign (57.14%) epithelial ovarian tumors, and normal ovarian tissue (20%; all P